Restless legs syndrome: differential diagnosis and management with pramipexole

Clinical Interventions in Aging, Jun 2009

Restless legs syndrome: differential diagnosis and management with pramipexole Francesca Brindani, Francesca Vitetta, Franco GemignaniDepartment of Neurosciences, University of Parma, ItalyAbstract: Restless legs syndrome (RLS) is a condition characterized by discomfort at rest and urge to move focused on the legs. RLS may occur as an idiopathic, often hereditary condition (primary RLS), or in association with medical conditions (secondary RLS) including iron deficiency, uremia, and polyneuropathy. Current understanding of the pathophysiology of RLS points to the involvement of three interrelated components: dopaminergic dysfunction, impaired iron homeostasis, and genetic mechanisms. The diagnosis of RLS is made according to the consensus criteria by a National Institutes of Health panel: 1) an urge to move the legs, usually accompanied by uncomfortable sensations; 2) beginning or worsening during rest; 3) relieved by movement; and 4) worse, or only occurring, in the evening or at night. The differential diagnosis of RLS aims to: 1) distinguish RLS from other disorders with RLS-like symptoms and 2) identify secondary forms, with investigation of underlying diseases. The treatment of RLS demands a clinical evaluation to rule out and cure causes of secondary RLS, including iron supplementation when deficient, and to eliminate the triggering factors. The presence of neuropathy should be especially investigated in nonhereditary, late-onset RLS, in view of a possible treatment of the underlying disease. The first line treatment for idiopathic RLS is represented by dopamine agonists, in particular nonergot-derived ropinirole and pramipexole, whereas ergot dopamine agonists (cabergoline and pergolide) are no longer in first-line use given the risks of cardiac valvulopathy. Although no comparative trials have been published, a meta-analysis of pramipexole versus ropinirole suggests differences in efficacy and tolerability favoring pramipexole.Keywords: restless legs syndrome, pramipexole, dopamine, agonists, small fiber neuropathy

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://www.dovepress.com/getfile.php?fileID=4967

Restless legs syndrome: differential diagnosis and management with pramipexole

Clinical Interventions in Aging restless legs syndrome: differential diagnosis and management with pramipexole 0 Department of Neurosciences, University of Parma , Italy Restless legs syndrome (RLS) is a condition characterized by discomfort at rest and urge to move focused on the legs. RLS may occur as an idiopathic, often hereditary condition (primary RLS), or in association with medical conditions (secondary RLS) including iron deficiency, uremia, and polyneuropathy. Current understanding of the pathophysiology of RLS points to the involvement of three interrelated components: dopaminergic dysfunction, impaired iron homeostasis, and genetic mechanisms. The diagnosis of RLS is made according to the consensus criteria by a National Institutes of Health panel: 1) an urge to move the legs, usually accompanied by uncomfortable sensations; 2) beginning or worsening during rest; 3) relieved by movement; and 4) worse, or only occurring, in the evening or at night. The differential diagnosis of RLS aims to: 1) distinguish RLS from other disorders with RLS-like symptoms and 2) identify secondary forms, with investigation of underlying diseases. The treatment of RLS demands a clinical evaluation to rule out and cure causes of secondary RLS, including iron supplementation when deficient, and to eliminate the triggering factors. The presence of neuropathy should be especially investigated in nonhereditary, late-onset RLS, in view of a possible treatment of the underlying disease. The first line treatment for idiopathic RLS is represented by dopamine agonists, in particular nonergot-derived ropinirole and pramipexole, whereas ergot dopamine agonists (cabergoline and pergolide) are no longer in first-line use given the risks of cardiac valvulopathy. Although no comparative trials have been published, a meta-analysis of pramipexole versus ropinirole suggests differences in efficacy and tolerability favoring pramipexole. - 8 1 0 2 l u J 3 1 n o 7 5 1 . 9 2 1 . 6 9 1 . 5 y b / m o c . s s e end-stage renal diseases,9 pregnancy,10 rheumatologic disorders,11,12 diabetes,13,14 as well as neurologic conditions such as Parkinson’s disease,15 spinal cord lesions,16 multiple sclerosis,18 and polyneuropathy.18 The association of RLS with polyneuropathy is of particular interest from epidemiological, mechanistic, and diagnostic viewpoints, but is still controversial, in spite of extensive studies. Prevalence estimates of RLS in neuropathy are extremely variable, ranging from 5.2%19 to 54%.20 In a series of 104 consecutive patients with miscellaneous neuropathies, we found a 29% prevalence of RLS, compared to 9% in controls.18 A prevalence of RLS of 54% was found in a selected series of patients with neuropathy with symptoms of pain or dysesthesia.20 On the contrary, in a recent controlled, double-blind study, the prevalence of RLS in neuropathy patients (12.2%) did not differ significantly from controls (8.2%), but in the subgroup of patients with hereditary neuropathy a higher prevalence of 19.4% was .rvdoepww ll.syeuon fdoisucnrde.p21anCcoiensfliincttihneg dreessiuglntsomf athyebsetudduieestaonmdeinthtohdeoalossgeiscsa-l ://sw oan ment of RLS and of neuropathy, and variations in etiology h pe of neuropathy between cohorts; in addition, it should be ttp rs from roF considered that, as polyneuropathy is usually an evolutive de condition, the appearance or disappearance of RLS may be laod related to different phases of the disease. As it has been shown onw that RLS can be triggered by small fiber sensory neuropangd thy,18,22–24 it is expected that RLS prevalence in neuropathy igA will be higher when considering the forms with prevailing isn small fiber involvement, such as diabetic neuropathy.14,25 In itnno conclusion, we think that the prevalence of RLS in the course ltIrvnee doifffpeorleynntesuurbotpyapthesy, ssheogureldgabteedfueritthheerr absyseestsieodlosgeypaorratoenlythine ilicanC basiCsuorfrepnretfuenrednetrisatlalnydiinnvgolovfedthneeprvaethfoibpehrypsiooplouglaytioonf.RLS points to the involvement of three interrelated components: dopaminergic dysfunction, impaired iron homeostasis, and genetic mechanisms.26 In particular, dopamine dysfunction plays a central role, as suggested by the early observation that dopaminergic drugs are highly effective in treating RLS.27 Increasing data support the hypothesis that dysfunctioning dopaminergic pathway resides in the small diencephalospinal tract originating from the hypothalamic A11 nucleus,16 modulating the excitability of sensorimotor spinal circuits presumably subserving RLS.28,29 Dysfunction of endogenous opioidergic circuits, possibly mediated by an interaction with the dopaminergic system, has been also implicated, based on the positive clinical response to opioidergic agents.30 Recently, in a PET study with an aspecific opioid submit your manuscript | www.dovepress.com Dovepress receptor ligand, von Spiczak and colleagues found a negative correlation between RLS sever (...truncated)


This is a preview of a remote PDF: https://www.dovepress.com/getfile.php?fileID=4967

Francesca Brindani, Francesca Vitetta, Franco Gemignani. Restless legs syndrome: differential diagnosis and management with pramipexole, Clinical Interventions in Aging, 2009, pp. 305-313, DOI: 10.2147/CIA.S4143